{"result": "(\"entity\"<|>MAGNESIO<|>ORGANIZATION<|>Magnesium is an essential mineral that plays a critical role in various bodily functions, including muscle and nerve function, and is often involved in electrolyte balance.)\n##\n(\"entity\"<|>CALCIO<|>ORGANIZATION<|>Calcium is a vital mineral necessary for various physiological processes, including bone health and muscle function, and is often discussed in the context of electrolyte balance.)\n##\n(\"entity\"<|>ALCOHOLISMO<|>EVENT<|>A condition characterized by an addiction to alcohol, which can lead to various health issues, including electrolyte imbalances such as hypomagnesemia.)\n##\n(\"entity\"<|>DESNUTRICIÓN<|>EVENT<|>A state of poor nutrition that can result from inadequate intake of nutrients, leading to various health complications, including electrolyte disturbances.)\n##\n(\"entity\"<|>CÁNCER<|>EVENT<|>A disease characterized by uncontrolled cell growth, which can affect nutritional status and lead to electrolyte imbalances, including hypomagnesemia.)\n##\n(\"entity\"<|>HEPATOPATÍA<|>EVENT<|>Liver disease that can impact the body's ability to regulate electrolytes, potentially leading to conditions like hypomagnesemia.)\n##\n(\"entity\"<|>HIPOCALEMIA<|>EVENT<|>A condition characterized by low potassium levels in the blood, which can be associated with hypomagnesemia and other electrolyte imbalances.)\n##\n(\"entity\"<|>HIPOCLOROSEMIA<|>EVENT<|>A condition of low chloride levels in the blood, which can occur alongside other electrolyte disturbances, including hypomagnesemia.)\n##\n(\"entity\"<|>HIDRATACIÓN<|>EVENT<|>The process of providing adequate fluids to the body, which is crucial for maintaining electrolyte balance, including magnesium levels.)\n##\n(\"entity\"<|>TRATAMIENTO CON RESTRICCIÓN HÍDRICA<|>EVENT<|>A treatment approach for chronic hyponatremia that involves limiting fluid intake to help correct sodium levels.)\n##\n(\"entity\"<|>TERAPIA CON SOLUTOS<|>EVENT<|>A treatment method involving the administration of solutes, such as urea or sodium chloride, to manage electrolyte imbalances.)\n##\n(\"relationship\"<|>MAGNESIO<|>HIPOMAGNESEMIA<|>Magnesium levels are critical for maintaining electrolyte balance, and low levels can lead to hypomagnesemia<|>8)\n##\n(\"relationship\"<|>CALCIO<|>HIPOCALCEMIA<|>Calcium levels are essential for various bodily functions, and low levels can lead to hypocalcemia, which may be associated with magnesium imbalances<|>7)\n##\n(\"relationship\"<|>ALCOHOLISMO<|>HIPOMAGNESEMIA<|>Alcoholism can lead to direct renal losses of magnesium, contributing to hypomagnesemia<|>6)\n##\n(\"relationship\"<|>DESNUTRICIÓN<|>HIPOMAGNESEMIA<|>Malnutrition can result in electrolyte imbalances, including low magnesium levels<|>6)\n##\n(\"relationship\"<|>CÁNCER<|>HIPOMAGNESEMIA<|>Cancer can affect nutritional status and lead to electrolyte disturbances, including hypomagnesemia<|>6)\n##\n(\"relationship\"<|>HEPATOPATÍA<|>HIPOMAGNESEMIA<|>Liver disease can impair the regulation of electrolytes, potentially leading to hypomagnesemia<|>6)\n##\n(\"relationship\"<|>HIPOCALEMIA<|>HIPOMAGNESEMIA<|>Low potassium levels can be associated with low magnesium levels, creating a cycle of electrolyte imbalances<|>6)\n##\n(\"relationship\"<|>HIDRATACIÓN<|>HIPONATREMIA<|>Proper hydration is essential for maintaining sodium levels, and inadequate hydration can lead to hyponatremia<|>7)\n##\n(\"relationship\"<|>TRATAMIENTO CON RESTRICCIÓN HÍDRICA<|>HIPONATREMIA<|>Fluid restriction is a common treatment for chronic hyponatremia to help correct sodium levels<|>8)\n##\n(\"relationship\"<|>TERAPIA CON SOLUTOS<|>HIPONATREMIA<|>Solute therapy can be used to manage chronic hyponatremia by providing necessary electrolytes<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: observarse igualmente en pancreatitis\n         1.   Hiponatremia aguda (<48 h) con clínica moderada-grave de hiponatremia con natremia                                                aguda     (saponificación de         magnesio       y calcio    en la   grasa necrótica). Igualmente              se ha\n              previa al cuadro normal: no existe límite de corrección dado que el riesgo de síndrome                                            descrito en relación con el uso crónico de inhibidor de la bomba de protones, pudiendo\n              de desmielinización osmótica (SDO) es extremadamente bajo en este contexto.                                                       estar exacerbado si se utiliza de manera concomitante diuréticos de asa.\n         2.   Hiponatremia crónica (>48 h) o de duración indeterminada:                                                                     2.  Pérdidas renales: tanto los diuréticos tiazídicos como de asa pueden producir hipomag-\n                                                                                                                                                nesemia a menudo de intensidad leve. Otros fármacos nefrotóxicos que llevan a hipo-\n              a.  Sin riesgo de SDO: no sobrepasar los 10-12 mmol/l en ningún periodo de 24 horas.                                              magnesemia son: aminoglucósidos, anfotericina B, cisplatino, pentamidina, inhibidores\n              b.  Con factores de        riesgo de SDO (alcoholismo, desnutrición, cáncer, hepatopatía): no                                     de la calcineurina, como la ciclosporina o el tacrolimus, digoxina o anticuerpos frente al\n                  sobrepasar los 6-8 mmol/l en ningún periodo de 24 horas.                                                                      receptor del factor de crecimiento epitelial (EGF receptor) como el cetuximab. También\n                                                                                                                                                se observa en ingesta crónica de alcohol por toxicidad tubular directa por el alcohol.\n         En la respuesta B nos dan la severidad, pero no nos indican si es aguda o crónica, ni si                                               Otros: síndrome de Gitelman o Bartter, disfunción tubular transitoria tras uropatía obs-\n         presenta factores de riesgo de SDO.                                                                                                    tructiva bilateral, etc.\n         En pacientes con hiponatremia crónica oligosintomática, las guías clínicas americanas y                                            La hipomagnesemia tiende a asociarse a hipopotasemia (secundario a pérdidas renales) e\n         europeas, respectivamente, recomiendan tratamiento con restricción hídrica como primera                                            hipocalcemia (la hipomagnesemia disminuye la liberación de PTH y produce resistencia a\n         alternativa, aunque la evidencia para esta recomendación es baja. Otras alternativas que                                           nivel tisular).\n         no han demostrado ser más útiles que placebo (por ausencia de estudios comparativos)                                               En la insuficiencia renal crónica se produce un defecto de eliminación del magnesio plas-\n         además de la restricción hídrica serían la terapia con solutos como suplementos de urea o                                          mático por menor capacidad de eliminación renal, con tendencia a la hipermagnesemia,\n         de cloruro sódico vía oral.                                                                                                        dado que no existe otro mecanismo de regulación fuera de la excreción urinaria.\n         Referencias:\n         • Cuesta M, Garrahy A, Slattery D, Gupta S, Hannon AM, Forde H, et al. The contribution of undiagnosed adrenal insufficiency       Referencias:\n           to euvolaemic hyponatraemia: results of a large prospective single-centre study. Clin Endocrinol (Oxf). 2016;85(6):836-44.       • Foster JE, Harpur ES, Garland HO. An investigation of the acute effect of gentamicin on the renal handling of electrolytes in the rat.\n         • Hoorn EJ, Rivadeneira F, van Meurs JB, Ziere G, Stricker BH, Hofman A, et al. Mild hyponatremia as a risk factor for fractures:    J Pharmacol Exp Ther. 1992;261:38.\n           the Rotterdam Study. J Bone Miner Res. 2011;26(8):1822-8.                                                                        • Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment\n         • Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Hyponatraemia Guideline Development Group.                 Pharmacol Ther. 2012;36:405.\n           Hyponatraemia diagnosis and treatment clinical practice guidelines. Nefrologia. 2017;37(4):370-80.                               • Lajer H, Kristensen M, Hansen HH, Christensen S, Jonassen T, Daugaard G. Magnesium and potassium homeostasis during cisplatin\n         • Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment            treatment. Cancer Chemother Pharmacol.\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>HIPONATREMIA AGUDA<|>EVENT<|>Acute hyponatremia characterized by moderate to severe clinical symptoms and low sodium levels within 48 hours, often associated with necrotic fat saponification of magnesium and calcium.)\n##\n(\"entity\"<|>HIPONATREMIA CRÓNICA<|>EVENT<|>Chronic hyponatremia lasting more than 48 hours, which can lead to various complications and is categorized based on the risk of osmotic demyelination syndrome.)\n##\n(\"entity\"<|>SÍNDROME DE DESMIELINIZACIÓN OSMÓTICA<|>EVENT<|>A rare but serious condition that can occur due to rapid correction of hyponatremia, leading to neurological damage.)\n##\n(\"entity\"<|>DIURÉTICOS DE ASA<|>ORGANIZATION<|>Loop diuretics that can cause renal losses of magnesium and contribute to hypomagnesemia.)\n##\n(\"entity\"<|>DIURÉTICOS TIAZÍDICOS<|>ORGANIZATION<|>Thiazide diuretics that can also lead to renal losses of magnesium, often resulting in mild hypomagnesemia.)\n##\n(\"entity\"<|>CICLOSPORINA<|>ORGANIZATION<|>An immunosuppressant drug that can cause hypomagnesemia as a side effect.)\n##\n(\"entity\"<|>TACROLIMUS<|>ORGANIZATION<|>Another immunosuppressant that may lead to low magnesium levels in patients.)\n##\n(\"entity\"<|>DIGOXINA<|>ORGANIZATION<|>A medication used to treat heart conditions that can affect magnesium levels.)\n##\n(\"entity\"<|>ANTICUERPOS FRENTE AL RECEPTOR DEL FACTOR DE CRECIMIENTO EPITELIAL<|>ORGANIZATION<|>Antibodies targeting the epidermal growth factor receptor, which can also lead to hypomagnesemia.)\n##\n(\"entity\"<|>SÍNDROME DE GITELMAN<|>EVENT<|>A genetic disorder characterized by renal magnesium wasting and hypomagnesemia.)\n##\n(\"entity\"<|>SÍNDROME DE BARTTER<|>EVENT<|>A group of rare kidney disorders that lead to electrolyte imbalances, including hypomagnesemia.)\n##\n(\"entity\"<|>INSUFICIENCIA RENAL CRÓNICA<|>EVENT<|>A long-term condition where the kidneys do not function effectively, often leading to magnesium retention and potential hypermagnesemia.)\n##\n(\"relationship\"<|>HIPONATREMIA AGUDA<|>SÍNDROME DE DESMIELINIZACIÓN OSMÓTICA<|>Acute hyponatremia can lead to the risk of osmotic demyelination syndrome if sodium levels are corrected too quickly<|>8)\n##\n(\"relationship\"<|>HIPONATREMIA CRÓNICA<|>SÍNDROME DE DESMIELINIZACIÓN OSMÓTICA<|>Chronic hyponatremia can present risks for osmotic demyelination syndrome, especially with rapid correction<|>7)\n##\n(\"relationship\"<|>DIURÉTICOS DE ASA<|>HIPONATREMIA CRÓNICA<|>Loop diuretics can cause renal losses of magnesium, contributing to chronic hyponatremia<|>6)\n##\n(\"relationship\"<|>DIURÉTICOS TIAZÍDICOS<|>HIPONATREMIA CRÓNICA<|>Thiazide diuretics can also lead to magnesium loss, which may exacerbate chronic hyponatremia<|>6)\n##\n(\"relationship\"<|>CICLOSPORINA<|>HIPONATREMIA CRÓNICA<|>Cyclosporine can induce hypomagnesemia, which may be a factor in chronic hyponatremia<|>5)\n##\n(\"relationship\"<|>TACROLIMUS<|>HIPONATREMIA CRÓNICA<|>Tacrolimus can lead to low magnesium levels, potentially affecting chronic hyponatremia<|>5)\n##\n(\"relationship\"<|>DIGOXINA<|>HIPONATREMIA CRÓNICA<|>Digoxin can influence magnesium levels, which may be relevant in chronic hyponatremia cases<|>5)\n##\n(\"relationship\"<|>ANTICUERPOS FRENTE AL RECEPTOR DEL FACTOR DE CRECIMIENTO EPITELIAL<|>HIPONATREMIA CRÓNICA<|>Antibodies against the EGF receptor can lead to hypomagnesemia, impacting chronic hyponatremia<|>5)\n##\n(\"relationship\"<|>SÍNDROME DE GITELMAN<|>HIPONATREMIA CRÓNICA<|>Gitelman syndrome is characterized by renal magnesium wasting, which can contribute to chronic hyponatremia<|>6)\n##\n(\"relationship\"<|>SÍNDROME DE BARTTER<|>HIPONATREMIA CRÓNICA<|>Bartter syndrome can lead to electrolyte imbalances, including chronic hyponatremia<|>6)\n##\n(\"relationship\"<|>INSUFICIENCIA RENAL CRÓNICA<|>HIPONATREMIA CRÓNICA<|>Chronic kidney disease can lead to magnesium retention and affect sodium levels, contributing to chronic hyponatremia<|>7)\n<|COMPLETE|>"}]}